KR20070043795A - 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법 - Google Patents

톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법 Download PDF

Info

Publication number
KR20070043795A
KR20070043795A KR1020077001407A KR20077001407A KR20070043795A KR 20070043795 A KR20070043795 A KR 20070043795A KR 1020077001407 A KR1020077001407 A KR 1020077001407A KR 20077001407 A KR20077001407 A KR 20077001407A KR 20070043795 A KR20070043795 A KR 20070043795A
Authority
KR
South Korea
Prior art keywords
cells
poly
tlr
tlr3
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077001407A
Other languages
English (en)
Korean (ko)
Inventor
세르게 레벡꾸에
토우픽 렌노
부루노 살라운
이사벨 코스테-인베르니찌
마리-끌로띨데 리쏘앙
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20070043795A publication Critical patent/KR20070043795A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077001407A 2004-07-20 2005-07-19 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법 Ceased KR20070043795A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58961604P 2004-07-20 2004-07-20
US60/589,616 2004-07-20

Publications (1)

Publication Number Publication Date
KR20070043795A true KR20070043795A (ko) 2007-04-25

Family

ID=35229744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077001407A Ceased KR20070043795A (ko) 2004-07-20 2005-07-19 톨-유사 수용체 발현 종양 세포에서 세포자멸사의 유도방법

Country Status (12)

Country Link
US (2) US20060147456A1 (cg-RX-API-DMAC7.html)
EP (1) EP1768699A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008507530A (cg-RX-API-DMAC7.html)
KR (1) KR20070043795A (cg-RX-API-DMAC7.html)
CN (1) CN101018567B (cg-RX-API-DMAC7.html)
AT (1) ATE511859T1 (cg-RX-API-DMAC7.html)
AU (2) AU2005269733B2 (cg-RX-API-DMAC7.html)
CA (1) CA2574176A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007000770A (cg-RX-API-DMAC7.html)
NO (1) NO20070945L (cg-RX-API-DMAC7.html)
RU (1) RU2401661C9 (cg-RX-API-DMAC7.html)
WO (1) WO2006014653A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Tlr 작동제를 포함하는 유방암 방사선 치료 보조제

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス,インコーポレイテッド 細胞死及び/又はアポトーシスを誘導するための、選択されたrnaモチーフ
WO2006054129A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20120189643A1 (en) * 2004-11-30 2012-07-26 Carton Jill M Toll Like Receptor 3 Antagonists, Methods and Uses
EP1993553B1 (en) 2006-03-02 2013-05-08 Agency for Science, Technology and Research Methods for cancer therapy and stem cell modulation
AU2007249698A1 (en) 2006-05-15 2007-11-22 University Of Kentucky Toll-like receptor (TLR) stimulation for ocular angiogenesis and macular degeneration
EP1881080A1 (en) * 2006-07-18 2008-01-23 Institut Gustave Roussy Toll like receptor 4 dysfunction and the biological applications thereof
US20080124366A1 (en) * 2006-08-06 2008-05-29 Ohlfest John R Methods and Compositions for Treating Tumors
JP5115921B2 (ja) * 2007-02-28 2013-01-09 株式会社ペルセウスプロテオミクス 腎癌の診断薬および治療薬
AU2008242540A1 (en) * 2007-04-24 2008-10-30 John Wayne Cancer Institute Functional toll-like receptors (TLR) on melanocytes and melanoma cells and uses thereof
JP2011504462A (ja) * 2007-11-02 2011-02-10 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 腫瘍の予防および治療のための方法および化合物
WO2009073152A1 (en) * 2007-11-28 2009-06-11 Smart Tube, Inc. Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
AU2009215795A1 (en) * 2008-02-21 2009-08-27 University Of Kentucky Research Foundation Ultra-small RNAs as toll-like receptor-3 antagonists
AU2009239655B2 (en) 2008-04-25 2014-05-22 Innate Pharma Improved TLR3 agonist compositions
WO2010020590A1 (en) * 2008-08-20 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators
US8628762B2 (en) 2008-12-10 2014-01-14 Icahn School Of Medicine At Mount Sinai T-helper cell type 17 lineage-specific adjuvants, compositions and methods
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
US9090897B2 (en) * 2009-12-18 2015-07-28 Bavarian Nordic A/S Production of IFN-lambda by conventional dendritic cells
RU2014103159A (ru) * 2011-07-22 2015-08-27 Павел КАЛИНСКИЙ Опухолесективная модуляция хемокинов
CN102652802A (zh) * 2012-04-18 2012-09-05 南京中医药大学 癌毒方在制备调控肝癌细胞TLRs/NF-κB信号转导药物中的应用
EP2879669A4 (en) 2012-07-29 2016-04-13 Univ Colorado Regents ANTAGONISTS OF THE TOLL LIKE RECEPTOR 1/2 COMPLEX
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN105796594A (zh) * 2016-03-28 2016-07-27 南京大学 一种组合物在制备治疗肿瘤药物中的应用及该组合物的使用方法
CN106191238B (zh) * 2016-07-08 2020-01-10 中国医学科学院基础医学研究所 Tlr3预测肿瘤转移、评估预后和选择防治方案的应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN108295060A (zh) * 2018-04-08 2018-07-20 王长国 一种tlr7激动剂在增强cik细胞对肿瘤细胞杀伤力方面的应用
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111117966A (zh) * 2020-03-02 2020-05-08 南通大学 一种利用乳酸的体外细胞培养方法
CN111579538B (zh) * 2020-04-22 2022-12-30 山东第一医科大学(山东省医学科学院) 一种利用凋亡试剂盒检测循环肿瘤细胞的方法
KR20220158640A (ko) * 2021-05-24 2022-12-01 주식회사 차백신연구소 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물
CN115820646A (zh) * 2022-12-20 2023-03-21 武汉光谷中源药业有限公司 一种增强免疫能力的免疫激动剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CN1040504A (zh) * 1988-06-22 1990-03-21 Hem研究公司 用双链核糖核酸调节淋巴激活素抗性细胞状态
RU2136278C1 (ru) * 1998-04-07 1999-09-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Противоопухолевое средство
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
EP1412390A2 (en) * 2001-07-26 2004-04-28 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
WO2004047612A2 (en) * 2002-11-22 2004-06-10 Nuvelo, Inc. Methods of therapy and diagnosis
JP3810731B2 (ja) * 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のToll様受容体3に結合する新規アダプタータンパク質およびその遺伝子

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101250419B1 (ko) * 2010-12-16 2013-04-05 강원대학교산학협력단 Tlr 작동제를 포함하는 유방암 방사선 치료 보조제

Also Published As

Publication number Publication date
EP1768699A1 (en) 2007-04-04
CN101018567B (zh) 2011-07-27
AU2005269733A1 (en) 2006-02-09
US20090285779A1 (en) 2009-11-19
RU2401661C9 (ru) 2011-01-27
AU2005269733B2 (en) 2008-10-30
MX2007000770A (es) 2007-03-26
US20060147456A1 (en) 2006-07-06
JP2008507530A (ja) 2008-03-13
RU2007105987A (ru) 2008-08-27
RU2401661C2 (ru) 2010-10-20
CA2574176A1 (en) 2006-02-09
CN101018567A (zh) 2007-08-15
NO20070945L (no) 2007-02-19
ATE511859T1 (de) 2011-06-15
WO2006014653A1 (en) 2006-02-09
AU2008249173A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
AU2005269733B2 (en) Induction of apoptosis in Toll-like receptor expressing tumor cells
US20240043541A1 (en) Methods for treating hematologic cancers
Jing et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US20150132226A1 (en) Treatment of cancer
US20090191185A1 (en) Reducing Cancer Cell Invasion Using an Inhibitor of Toll Like Receptor Signaling
KR20200026209A (ko) Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
Luo et al. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo
TW201919706A (zh) 包含il-33拮抗劑的子宮內膜異位症治療劑
Kulshrestha et al. In vivo anti‐V‐ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses
Ganor et al. Human T-leukemia and T-lymphoma express glutamate receptor AMPA GluR3, and the neurotransmitter glutamate elevates the cancer-related matrix-metalloproteinases inducer CD147/EMMPRIN, MMP-9 secretion and engraftment of T-leukemia in vivo
BR112021004417A2 (pt) métodos para tratar câncer pela inibição de enzima e2 k de conjugação de ubiquitina (ube2k)
JP2022502517A (ja) ヒトdickkopf3に対するモノクローナル抗体およびその使用方法
US20140348744A1 (en) Compositions and methods for regulating cancer-related signaling pathways
Wang et al. Nifuroxazide in combination with CpG ODN exerts greater efficacy against hepatocellular carcinoma
JP5695905B2 (ja) Nlrr−1アンタゴニスト及びその使用
TWI730450B (zh) 抗體,包含該抗體的套組,以及其用途
JP2010540653A5 (cg-RX-API-DMAC7.html)
US9868792B2 (en) Methods of enhancing anti-tumor immunity by administering antibodies to the CCRL2 chemerin receptor
KR20180125906A (ko) 항암 치료 효과 증진용 약학 조성물
US20230331849A1 (en) CpG IMMUNOCONJUGATES FOR CANCER THERAPY
Salem The role of CCR7 axis in facilitating chemoresistance, radioresistance and induction of cell proliferation in cancer
Parihar Characterization of the natural killer cell cytokine response to antibody-coated tumor cells
KR20150094527A (ko) Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물
TW201919694A (zh) Cd14拮抗分子用於治療癌症

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070119

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120523

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120726

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I